DEFA14A: STAAR Surgical Delays Alcon Merger Vote

STAAR Surgical Company has postponed its special meeting to vote on the proposed $28.00 per share cash merger with Alcon Research, LLC until December 3, 2025, amidst significant shareholder opposition.

Summary

• STAAR Surgical Company (STAAR) entered into a Merger Agreement with Alcon Research, LLC (Alcon) and Rascasse Merger Sub, Inc. on August 4, 2025.
• If the Merger is completed, STAAR stockholders will receive $28.00 in cash for each share, representing an approximately 59% premium to the 90-day volume weighted average price and a 51% premium to the closing price on August 4, 2025.
• The Special Meeting to vote on the Merger Proposal and a non-binding Compensation Proposal has been postponed from October 23, 2025, and then November 6, 2025, to December 3, 2025, at 8:30 a.m. Pacific Time.
• The record date for the Special Meeting has been reset from September 12, 2025, to October 24, 2025.
• The STAAR Board of Directors has unanimously approved the Merger Agreement and recommends stockholders vote FOR both proposals.
• Broadwood Partners, L.P. (Broadwood Group), holding 27.4% of outstanding shares, and Yunqi Capital Limited (5.1%) have publicly announced their opposition to the Merger Proposal.
• Soleus Capital Master Fund, L.P., a significant stockholder (6.0%), has stated its support for the Merger Proposal.
• Proxy advisory firms Glass Lewis & Co. LLC, Egan-Jones Proxy Services, and Institutional Shareholder Services have recommended AGAINST the Merger Proposal and Compensation Proposal.
• The required affirmative vote for the Merger Proposal is a majority of the outstanding shares, which is 24,682,912 shares as of the new Record Date.
• Two lawsuits (Smith v. STAAR Surgical Company et al., Miller v. STAAR Surgical Company et al.) and several demand letters allege misrepresentations/omissions in the proxy statement regarding the merger.
• STAAR received no competing proposals during the 45-day 'window shop' period, which ended September 19, 2025.

Sentiment

Score: 4

Explanation: The filing details a proposed merger with a substantial premium, which is positive. However, the significant opposition from major shareholders and proxy advisory firms, coupled with the postponement of the special meeting and Alcon's refusal to increase the offer, introduces considerable uncertainty and risk to the transaction's completion. The ongoing proxy contest and legal challenges further complicate the situation.

Positives

• The merger consideration of $28.00 per share in cash represents a significant premium.
• The offer is an approximately 59% premium to the 90-day volume weighted average price of STAAR common stock on August 4, 2025.
• The offer is an approximately 51% premium to the closing price of STAAR common stock on August 4, 2025.
• STAAR's Board of Directors has unanimously approved the Merger Agreement and recommends its adoption.
• Soleus Capital Master Fund, L.P., a beneficial owner of approximately 6.0% of outstanding shares, is supportive of and intends to vote in favor of the Merger Proposal.

Negatives

• Significant shareholder opposition from Broadwood Partners, L.P. (27.4% ownership) and Yunqi Capital Limited (5.1% ownership) to the Merger Proposal.
• Proxy advisory firms Glass Lewis & Co. LLC, Egan-Jones Proxy Services, and Institutional Shareholder Services have recommended AGAINST both the Merger Proposal and the Compensation Proposal.
• An ongoing proxy contest initiated by the Broadwood Group is causing additional solicitation and other costs and may impair STAAR's ability to obtain the required votes.
• Two individual lawsuits and several demand letters allege misrepresentations and/or omissions in the proxy statement regarding the merger.
• Alcon rejected STAAR's request for an increase in the Merger Consideration during recent discussions.
• The Broadwood Group has notified the Board of its intent to call a special meeting of stockholders to seek the removal of Dr. Yeu, Mr. Farrell, and Mr. Arthur Butcher from the Company's Board.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Merger Agreement or extend the anticipated timetable for completion of the proposed transaction.
• Failure to obtain the Stockholder Approval, the likelihood of which is increased by the Broadwood Group's ongoing proxy contest and lack of amendment to the existing terms of the Merger Agreement.
• Failure to obtain certain required regulatory approvals or to satisfy any other closing conditions to the completion of the Merger within expected timeframes or at all.
• Disruption of management's attention from STAAR's ongoing business operations due to the Merger and efforts by the Broadwood Group and other stockholders to solicit votes in opposition or remove current directors and officers.
• Disruption from the Merger making it more difficult to maintain business, contractual, and operational relationships, including retaining key personnel and maintaining relationships with customers, distributors, and suppliers.
• The ability of STAAR to meet expectations regarding the timing and completion of the Merger.
• Certain restrictions during the pendency of the Merger that may impact STAAR's ability to pursue certain business opportunities or strategic transactions.
• The risk that any announcements relating to the Merger could have adverse effects on the market price of STAAR common stock.
• The outcome of any legal proceedings that may be instituted against STAAR or Alcon related to the Merger.
• The possibility that the price of STAAR common stock may decline significantly if the Merger is not consummated.
• The ability to continue STAAR's growth and profitability trajectory.
• STAAR's reliance on independent distributors in international markets.
• The risk of a slowdown or disruption to the Chinese economy.
• Global economic conditions and competition.
• Potential disruptions in STAAR's supply chain.
• Fluctuations in foreign currency exchange rates.
• International trade disputes (including involving tariffs) and substantial dependence on demand from Asia.
• Changes in effective tax rate or tax laws.
• Any disruption to STAAR's ability to manufacture Collamer or loss of use of STAAR's principal manufacturing facility.
• Potential losses due to product liability claims or product recalls.
• Exposure to environmental liability and risks associated with climate change.
• Data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations.
• Acquisitions of new technologies.
• The willingness of surgeons and patients to adopt a new or improved product and procedure.
• Extensive clinical trials and resources devoted to research and development.
• Changes in pricing and pricing controls.
• Compliance with and changes to applicable laws and regulations, including laws pertaining to healthcare fraud and abuse, and U.S. Food and Drug Administration or international regulations related to product approval.
• The discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action.

Future Outlook

The filing primarily focuses on the proposed merger and the process to obtain shareholder approval. It reiterates forward-looking statements from previous filings, noting that actual results may differ materially due to various risks, including the consummation of the merger, regulatory approvals, and market conditions. There is no new specific guidance on future financial performance beyond the context of the merger, but management noted uncertainty regarding the timing and durability of a recovery in refractive procedure volumes in China, which would impact revenue growth scenarios.

Management Comments

• The STAAR Board of Directors has unanimously approved the Merger Agreement and has recommended that STAAR stockholders vote in favor of adopting the Merger Agreement.
• We recommend that STAAR stockholders disregard any proxy card sent to them by or on behalf of any person other than STAAR, including any green proxy card and solicitation materials that may be sent to STAAR stockholders by or on behalf of Broadwood Group.
• The Board was of the view that there was unlikely to be a third party who would be able or willing to provide greater value for STAAR's stockholders on a timeline similar to the timeline Alcon was prepared to pursue to execute definitive agreements.
• STAAR believes that the Matters [lawsuits and demands] are without merit.

Industry Context

This announcement details a proposed acquisition of STAAR Surgical by Alcon, a major player in the eye care industry. The financial analyses by Citi compare STAAR to other medical device companies (SI-BONE, AtriCure, Carl Zeiss Meditec, Tandem Diabetes Care, RxSight) and precedent transactions in the medical technology sector. The discussion of competitive threats, potential trade wars, tariff risks, and price controls in China highlights broader challenges and opportunities within the global ophthalmology and medical device industry, particularly concerning international markets like China which significantly impact STAAR's revenue growth. The merger itself represents a potential consolidation within the specialized medical device sector, aiming to leverage synergies and market position.

Comparison to Industry Standards

• Selected Public Companies Analysis: STAAR's implied per share equity value reference range of $16.35 to $23.80 (based on EV / 2026E Revenue multiples of 1.9x to 3.1x, with selected companies ranging from 0.7x to 3.1x) is below the Merger Consideration of $28.00.
• Selected Precedent Transactions Analysis: STAAR's implied per share equity value reference range of $17.15 to $30.80 (based on EV / LTM Revenue multiples of 3.1x to 6.3x, with selected transactions ranging from 3.1x to 6.3x) encompasses the Merger Consideration of $28.00.
• Discounted Cash Flow Analysis: STAAR's implied per share equity value reference range of $17.70 to $37.50 (based on revenue exit multiples of 2.5x to 6.5x and discount rates of 13.4% to 14.6%) also encompasses the Merger Consideration of $28.00.
• Discounted Equity Research Analyst Price Targets: The discounted range of $11.75 to $24.40 is below the Merger Consideration of $28.00.
• Median One-Day Unaffected Stock Price Premium: The 59% premium offered by Alcon significantly exceeds the median 26% premium observed in 24 comparable acquisition transactions since January 1, 2015.

Management Changes

Corporate Governance

Legal Proceedings

• Smith v. STAAR Surgical Company et al., Index No. 55858/2025 (filed October 1, 2025, Supreme Court of the State of New York, County of New York), alleging misrepresentations/omissions in the proxy statement and seeking an injunction against the merger, rescission, or damages.
• Miller v. STAAR Surgical Company et al., Index No. 55880/2025 (filed October 1, 2025, Supreme Court of the State of New York, County of New York), alleging similar deficiencies and seeking comparable relief.
• Several purported stockholders sent demand letters alleging similar disclosure deficiencies regarding the preliminary proxy and proxy statement.
• Appraisal demands have been received from the Broadwood Group and Yunqi Capital Limited.

Stakeholder Impact

• Shareholders: Will receive $28.00 cash per share if the merger is approved, representing a significant premium. However, dissenting shareholders (Broadwood, Yunqi) believe the offer is insufficient, and the postponement and proxy contest create uncertainty regarding the transaction's completion.
• Employees: The merger will result in STAAR becoming a wholly owned subsidiary of Alcon, which could impact employment terms, roles, and retention.
• Customers, Distributors, Suppliers: The announcement of the merger and ongoing disruptions could make it more difficult for STAAR to maintain existing business relationships.
• Management: Management's attention is disrupted by the merger process and proxy contest. Executive officers may receive compensation related to the merger, subject to shareholder approval.

Next Steps

• Stockholders are urged to submit votes via the updated WHITE proxy card by December 2, 2025, 11:59 p.m. Eastern Time.
• The Special Meeting will be held virtually on December 3, 2025, at 8:30 a.m. Pacific Time, to vote on the Merger Proposal and Compensation Proposal.
• STAAR management is directed to engage in further discussions with Alcon regarding potential amendments to the Merger Agreement.
• The Broadwood Group intends to call a special meeting of stockholders to seek the removal of certain STAAR directors.

Key Dates

Recommendation

The proposed merger offers a substantial premium over recent trading prices, which is attractive. However, the significant shareholder opposition from major investors and proxy advisory firms, coupled with the postponement of the vote and Alcon's refusal to increase the offer, introduces considerable uncertainty about the merger's completion. The ongoing proxy contest and legal challenges further complicate the situation. Investors should hold to see the outcome of the December 3rd vote, as a failure to approve the merger could lead to a significant decline in share price, while approval would realize the premium. The current situation is highly fluid and speculative.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, Proxy Statement, Shareholder Vote, Special Meeting, STAA, Ophthalmology, Medical Devices, Corporate Governance, Proxy Contest, SEC Filing, Cash Merger, Stockholder Approval